demonstrated that metastatic colon cancer cells express the cardiac Na V 1.5 VASC a subunit. 13 Primary colon cancer (SW420) cells have lower levels of Na V 1.5 expression than metastatic (SW620) cells isolated from the same patient. Moreover, the level of Na V 1.5 expression correlates with their invasive potential. Inhibition of Na V 1.5 channels either by applying lidocaine or by siRNA-mediated knockdown reduces SW620 cell migration through a Matrigel membrane, an in vitro assay of metastatic invasion. 13 The local anaesthetic ropivacaine is frequently used to provide regional anaesthesia during surgical tumour excision. However, the effects of ropivacaine have not been tested on Na V 1.5 VASCs expressed by metastatic colon cancer cells. In this study, we identified Na V 1.5 VASC splice variants in SW620 cells and examined their sensitivities to block by ropivacaine. We also determined that ropivacaine potently inhibits the invasion of SW620 cells.
Methods

Cell culture and transfection
Human embryonic kidney (HEK293) cells and SW620 cells were obtained from American Type Culture Collection (Manassas, VA, USA) and cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (Invitrogen, Paisley, UK) at 378C and 5% CO 2 . Adult and neonatal Na V 1.5 cDNAs were subcloned into pcDNA3.1 vector (Invitrogen). As previously described, HEK293 cells were transfected using calcium phosphate precipitation with cDNA encoding green fluorescence protein to identify transfected cells. 14 For immunocytochemistry, cells
were seeded onto poly-L-lysine-coated coverslips in 24-well plates and transfected using lipofectamine (Invitrogen).
Mock transfections were performed, as necessary, using empty pcDNA3.1 vector.
Molecular biology
Total RNA from transfected HEK293 cells or SW620 cells was isolated using RNeasy (Qiagen, Manchester, UK) and reverse transcribed (RevertAid RT-PCR Kit, Thermo Scientific, Loughborough, UK) using a single reverse primer for the exon 10-11 boundary (primer P1, Table 1 ) of human SCN5A (RefSeq NG_008934.1). Single-stranded cDNAs were subsequently amplified by polymerase chain reaction (PCR) with high-fidelity Pfu polymerase (Thermo Scientific, Loughborough, UK) using primer P1, together with forward primers directed against the boundary of exon 5 and either exon 6A (primer P2, Table 1 ) or exon 6B (primer P3, Table 1 ) of human SCN5A. PCR products were analysed by agarose gel electrophoresis. Fragments corresponding to exon 6A and 6B were extracted from the gel and sequenced by the Ninewells Hospital Genetics Core Services Unit. To create pcDNA3.1-nNa V 1.5, we amplified mRNA fragments containing either exon 6A or 6B from SW620 spanning two unique restriction sites (XhoI and EcoRI) within the open reading frame of SCN5A using primers P4 and P5 (Table 1) . The fragments were replaced into the same region of pCDNA3.1-Na V 1.5. The mixed population of plasmids (containing different cDNAs with exons 6A and 6B) were transformed into DH5a (Invitrogen), and screened by colony PCR with primers P1 and P2, which specifically amplifies fragments containing exon 6A (0.53 kb in size). Twenty out of 30 colonies screened contained exon 6A.
Immunocytochemistry
HEK293 cells or SW620 cells on coverslips were fixed using 2% paraformaldehyde and incubated with a mouse anti-Na v 1.5 antibody (ASC-005, Alomone labs, Jerusalem, Israel) at a 1:1000 dilution. An anti-mouse secondary antibody conjugated to Alexa Fluor 488 (Invitrogen) was used to visualize primary antibody binding on a Leica SP-5 confocal microscope at 63× magnification. All image analyses were performed using ImageJ software (http://rsb.info.nih.gov/ij/index.html).
Electrophysiology
The whole-cell patch-clamp technique was used to record voltage-activated Na + currents from HEK293 cells expressing 
Invasion assay
The Matrigel invasion assay was used to investigate SW620 invasion. Boyden invasion chambers (BD Biosciences, Oxford, UK) were coated with Matrigel. SW620 cells were resuspended in DMEM containing 0.1% FBS. DMEM containing 10% FBS was used as a chemoattractant. Chambers were incubated for 48 h at 378C. Invading cells were fixed in 100% methanol and stained using 1% toluidine blue. Membranes were mounted onto coverslips and imaged using light microscopy.
From each membrane, the number of cells in six random fields was counted using an inverted microscope at 10× magnification. Counting was performed under blinded conditions.
Analysis
Current amplitudes were measured using pCLAMP8 software. Activation curves were derived from current-voltage relationships. Na + conductances were calculated by determining the driving force at each holding potential (up to 20 mV) established from the Na + equilibrium potential. Conductances were normalized to peak values in each cell. Steady-state inactivation data were normalized to peak. Activation and inactivation data were fitted with the Boltzmann functions.
14 Ropivacaine concentration-response data were fitted with a logistic function. Fit parameters were determined from data acquired from individual cells, and expressed as the mean [standard error of the mean (SEM)]. Statistical analyses were performed using the paired or unpaired t-test, or one-way analysis of variance (ANOVA), as appropriate. Fitting and statistical analyses were performed using GraphPad Prism software (La Jolla, CA, USA).
Results
SW620 colon cancer cells express adult and neonatal Na V 1.5 variants
Our previous immunocytochemical analysis of SW620 cells demonstrates that they express Na V 1.5 VASCs. 13 We used a similar approach here to detect Na V 1.5 protein in SW620 cells and HEK293 cells transfected with cDNAs encoding either the adult or neonatal Na V 1.5 splice variant (Fig. 1A) . The antibody labelled SW620 cells and both recombinant Na V 1.5 splice variants. We previously detected mRNA encoding the adult Na V 1.5 splice variant in SW620 cells. 13 Here, we designed primers specific for the alternatively spliced variants encoded by exons 6A (neonatal) and 6B (adult), respectively ( Fig. 1B ; Table 1 ). There was no detectable neonatal Na V 1.5 transcript in mocktransfected HEK cells or in those transfected with cDNA encoding the adult Na V 1.5 splice variant (Fig. 1C , left and middle panels). These data demonstrate that the primer for the neonatal Na V 1.5 splice variant is specific and does not amplify the adult variant. In contrast, we detected transcripts for both the adult and neonatal Na V 1.5 splice variants in SW620 cells (Fig. 1C , right panel). Sequencing of the PCR product confirmed that both variants were indeed present. We constructed the full-length cDNA encoding the neonatal Na V 1.5 splice variant by replacing nucleotides for exon 6B with those of exon 6A from SW620 transcripts (see the Methods section). Sequencing confirmed successful incorporation of exon 6A and this construct was used for immunocytochemistry in Figure 1A and for comparison with adult Na V 1.5 in subsequent electrophysiological experiments.
Functional properties of adult and neonatal Na V 1.5 VASCs
Since SW620 cells contain adult and neonatal splice variants of Na V 1.5, it is necessary to establish the properties of each VASC subtype. We used the whole-cell patch-clamp technique to characterize Na + currents mediated by recombinant adult and neonatal Na V 1.5 VASCs expressed either alone or in combination in HEK293 cells. Currents were activated by depolarizing cells from 280 mV to between 270 and +70 mV in 10 mV increments ( Fig. 2A) . The plot of current density vs voltage reveals that the peak amplitude occurred at 210 and 0 mV for adult and neonatal Na V 1.5 channels, respectively (Fig. 2B ). There was no difference between the peak current density values obtained from cells expressing either variant (Table 2) . Activation curves were generated by plotting the conductance at each voltage (normalized to maximum conductance) from HEK293 cells expressing recombinant Na V 1.5 channels. The mean values for V 1/2 of activation (SEM) were established from the Boltzmann fits to data recorded from each cell ( Table 2 ). Figure 2C represents the averaged activation curves for adult and neonatal Na V 1.5 channels both alone and in combination. Consistent with previous reports, neonatal Na V 1.5 channels exhibited a significantly more depolarized V 1/2 of activation compared with adult Na V 1.5 channels (Fig. 2C and Table 2 ). 15 Interestingly, in HEK293 cells transfected with equal amounts of cDNAs encoding the adult and neonatal variants, the V 1/2 of activation of Na V 1.5 channels resembled that determined from cells expressing neonatal Na V 1.5 channels alone. Steady-state inactivation data were recorded from HEK293 cells expressing adult and neonatal Na V 1.5 splice variants, either alone or in combination (Fig. 2D ). Cells were exposed to 100 ms prepulses to voltages between 2140 and 210 mV, as illustrated in the inset voltage protocol (Fig. 2A) . There was no significant difference between the values for V 1/2 derived from the Boltzmann fits to the inactivation curves (Table 2) . When superimposed, the activation and inactivation curves reveal the window current (Fig. 2E) . The region bounded by the curves indicates a range of steady-state voltages at which tonic current is available. Using amphotericin B perforated patch technique under current-clamp conditions, we found the membrane potential of SW620 cells to be 242 (8) mV (n¼4). The window current plots indicate a greater available steady-state current at 240 mV for neonatal compared with adult Na V 1.5 channels (Fig. 2E) . Indeed, as predicted by the window current analysis, the average residual current amplitudes remaining at the end of 20 ms voltage steps to 240 mV were significantly greater in cells expressing neonatal Na V 1.5 channels alone or in combination with adult Na V 1.5 The top panel illustrates the topology of the Na V 1.5 a subunit, with the region affected by alternative splicing of exons 6A and 6B highlighted in red. Exon 6 encodes part of the voltage sensor in the first domain of Na V 1.5 channel. 15 The lower panels illustrate the exon structure of adult (middle) and neonatal (bottom) isoforms of Na V 1.5. Alternative usage of either exon 6A or exon 6B leads to mRNA encoding nNa V 1.5 (neonatal) or Na V 1.5 (adult), respectively. The amino acid sequences encoded by the two exons are provided with non-conserved residues highlighted in red. (C) Ethidium bromide-stained DNA from RT-PCR products of mock or Na V 1.5-transfected HEK cells and SW620 cells. Either exon 6A or exon 6B specific primers were used. The presence of either exon 6A or exon 6B resulted in a 0.53 kb band. Na V 1.5-transfected HEK cells yielded a strong 0.53 kb band only when the exon 6B specific primer was used. SW620 cells yielded 0.53 kb bands when either exon 6A or 6B primers were used, suggesting that SW620 cells contain mRNA transcripts for Na V 1.5 and nNa V 1.5. Subsequent sequencing of these bands revealed that they indeed correspond to exon 6A and exon 6B of SCN5A, respectively. Table 2 . Data for nNa V 1.5 (open circles) exhibit a significantly dextral-shifted voltage-dependence of activation when compared with Na V 1.5 data (solid circles). When Na V 1.5 and nNa V 1.5 were co-expressed (triangles), the voltage-dependence of activation resembles that of nNa V 1.5 expressed alone. (D) Voltage-dependence of inactivation. Currents evoked using the voltage protocol in (A, bottom panel) were converted into conductance values and plotted as a percentage of maximum. Data were fitted with a Boltzmann function (see fitting parameters in Table 2 ). The voltage-dependence of inactivation of Na V 1.5 (solid circles), nNa V 1.5 (open circles), and a combination of both isoforms (triangles) did not significantly differ (Table 1) . (E) Plots of current availability (window currents) highlighting the region bounded by the Boltzmann fits of activation and inactivation for Na V 1.5 (solid lines) and nNa V 1.5 (dashed lines). The peak window current occurs with more depolarized potentials in nNa V 1.5 compared with Na V 1.5. (F) Sustained current amplitude at 240 mV. Bar graph shows the current remaining (as a percentage of maximum) after a step from a holding voltage of 280 to 240 mV. The residual current is significantly larger in cells expressing nNa V 1.5 or both Na V 1.5 and nNa V 1.5 compared with cells expressing Na V 1.5 alone (P,0.05, one-way ANOVA, post hoc Tukey test), consistent with the shift in peak window current seen in (E). channels, when compared with cells only expressing adult Na V 1.5 channels (Fig. 2F) .
Inhibition of adult and neonatal Na V 1.5 VASCs by ropivacaine
We examined the effects of ropivacaine (0.25 -25 mM) on currents mediated by recombinant adult and neonatal Na V 1.5 channels expressed in HEK293 cells (Fig. 3) . Ropivacaine caused a potent inhibition of both variants. There was no difference in the concentration-dependence of inhibition fitted using a logistics function. The fits yielded IC 50 values of 2.9 (0.7) mM (n¼3) and 3.5 (0.1) mM (n¼3) for adult and neonatal Na V 1.5 splice variants, respectively. We investigated whether ropivacaine (2.5 mM) differentially influenced the voltagedependence of activation or inactivation of the adult and neonatal Na V 1.5 variants. Paired recordings before and during steady-state inhibition revealed that ropivacaine suppressed the amplitude of currents mediated by either Na V 1.5 variant at all voltages (Fig. 4) . Ropivacaine also caused significant shifts in the V 1/2 of inactivation to more hyperpolarized potentials, which were 280 (5) mV (n¼6) and 279 (2) mV (n¼5) for adult and neonatal Na V 1.5 channels, respectively (Fig. 4) . Ropivacaine had no effect on the V 1/2 of activation for either variant (Fig. 4) . Ropivacaine also reduced the steady-state window current in cells expressing neonatal Na V 1.5 channels (Fig. 4) .
The area under the curve bounded by the activation and inactivation curves was significantly reduced from 159 (24) to 107 (11) (n¼5, P,0.05, paired t-test) in cells expressing neonatal Na V 1.5 channels. In contrast, the area under the curve bounded by activation and inactivation curves was not significantly influenced by ropivacaine in cells expressing adult Na V 1.5 channels (n¼6, P.0.1, paired t-test).
Ropivacaine inhibits invasion of SW620 cells through Matrigel
SW620 cells invade through Matrigel, a proprietary matrix used to mimic the epithelial basement membrane. 13 We examined the ability of SW620 cells to invade by using a range of Matrigel concentrations (10 -100 mg ml 21 ). We found that SW620 cells exhibit optimal invasion through a 50 mg ml 21 Matrigel membrane (Fig. 5A) . We previously demonstrated that tetrodotoxin and lidocaine both inhibit invasion of SW620 metastatic colon cancer cells through Matrigel, suggesting that invasion is attenuated by VASC inhibition. 13 Indeed, this action is likely to be mediated by inhibiting Na V 1.5 channels, since selective knockdown of the ion channel's expression using siRNA caused a similar reduction in invasion. We confirmed that lidocaine (10 mM) inhibits invasion at all Matrigel concentrations tested (Fig. 5A) . We also examined the effects of the VASC activator veratridine. Veratridine (10 mM) caused a significant increase in SW620 invasion, consistent with a positive contribution of Na V 1.5 activity to this process (Fig. 5B) . Ropivacaine caused a concentration-dependent inhibition of SW620 invasion. The IC 50 for the inhibition of SW620 invasion by ropivacaine (determined by fitting the data using a logistics function) was 3.8 mM (Fig. 5C ), similar to the IC 50 for its inhibition of Na + currents mediated by Na V 1.5 channels (Fig. 3) .
Discussion
We demonstrated that SW620 colon cancer cells express adult and neonatal Na V 1.5 splice variants. The two variants exhibited Table 2 Functional characteristics of recombinant Na V 1.5 isoforms. V 1/2 and slope values were taken from the Boltzmann fits to data from individual cells. t inact was taken from single exponential fits to the maximal current from each cell. Current densities were calculated by dividing the maximum current from each cell by the cell capacitance. Statistical analysis was performed using one-way ANOVA with a post hoc Tukey test. The V 1/2 of activation of nNa V 1.5 and the combination of Na V 1.5 and nNa V 1.5 differed statistically from Na V 1.5 alone (*P,0.05). All other parameters showed no significant difference. similar steady-state inactivation profiles, but different values for V 1/2 of activation. As reported previously, the neonatal variant requires significantly higher voltages for activation. 15 This is consistent with alternative splicing of exon 6 affecting the sequence of the initial voltage sensor. Neonatal Na V 1.5 VASCs also mediate a greater proportion of available sustained current at more depolarized potentials, such as 240 mV, the approximate membrane potential of SW620 cells. When expressed together, the functional characteristics of the neonatal variant were dominant. These findings suggest that the neonatal Na V 1.5 variant likely mediates a low level of tonic inward Na + current in SW620 cells.
Ropivacaine inhibited currents mediated by either adult or neonatal Na V 1.5 channels with similar potency. When applied at a concentration close to IC 50 , ropivacaine inhibited Na + currents mediated by either variant, regardless of the holding voltage, shifting inactivation to more hyperpolarized potentials without affecting the voltage-dependence of activation. These findings suggest that ropivacaine inhibits Na V 1.5 channels by stabilizing the inactivated state, a common mechanism of high potency blockof VASCs by local anaesthetics. 16 Importantly in the context of colon cancer cells, ropivacaine caused a reduction in the availabilityof sustained current mediated by neonatal Na V 1.5 channels. It is this reduction in steady-state current that likely underlies the observed inhibition of SW620 cell invasion through Matrigel. The potency of ropivacaine as an inhibitor of Na V 1.5-mediated current and SW620 cell invasion is similar, in keeping with the demonstration that invasive behaviour in SW620 cells requires functional Na V 1.5 channels. 13 Consistent with this, the VASC activator veratridine enhanced SW620 invasion through Matrigel. Retrospective analyses suggest that local anaesthetics reduce the likelihood of cancer recurrence after surgical tumour excision. 6 -9 If so, there are several mechanisms that may contribute to their beneficial effect. Regional nerve block reduces the requirement for general anaesthesia and opioids, which may have negative effects on the immune system, the stress response, and/or natural killer cells. Local anaesthetics may also have direct beneficial effects. Some local anaesthetics may be anti-inflammatory and/or interact with second messenger systems to reduce cell proliferation and migration. 17 The presence of VASCs on metastatic cancer cells (including those derived from breast, colon, prostate, and lung tissue) provides another direct target for the beneficial effects of local anaesthetics. 10 -13 Our demonstration that ropivacaine potently inhibits the activity of neonatal Na V 1.5 channels, a variant expressed by metastatic cancer cells derived from both colon and breast suggests that systemic local anaesthetic might contribute to the apparent beneficial effect of regional anaesthesia during tumour excision. 15 VASCs expressed by cancer cells are likely to be predominantly in the inactivated state, which has a high affinity for local anaesthetics. In contrast, high concentrations of local anaesthetics are required to block impulses in nerves in which VASCs rarely visit the inactivated state. 16 Clinical studies demonstrate that maximum circulating free ropivacaine concentrations after peripheral nerve block and epidural infusion range between 0.2 and 0.7 mg ml
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. 18 -22 This equates to a Lidocaine (10 mM) inhibited SW620 cell invasion at all Matrigel concentrations (*P,0.05; one-way ANOVA; post hoc Tukey test). (B) SW620 invasion is VASC activity dependent. The bar graph shows that the VASC activator veratridine (10 mM) potentiated SW620 invasion (P,0.05, t-test). (C) Ropivacaine inhibited SW620 invasion. The graph shows the effect of increasing concentrations of ropivacaine on SW620 invasion. The dotted line shows the logistic fit of the concentration-response relationship. The IC 50 of ropivacaine inhibition of SW620 invasion was 3.8 mM. Invasion was significantly reduced at 10, 30, and 100 mM ropivacaine (P,0.05; one-way ANOVA; post hoc Dunnett's test vs control values). maximum concentration of 2.4 mM, close to the IC 50 values for inhibition of both Na V 1.5 channel function and SW620 invasion. Therefore, it is possible that during regional anaesthesia, circulating ropivacaine may inhibit Na V 1.5 channel function on circulating colon cancercells, an action that attenuates invasion. While regional anaesthesia may help reduce cancer recurrence and metastases after tumour excision, direct local anaesthetic administration onto tumours and/or i.v. would likely maximize any direct beneficial effects. A drawback is the possibility of toxicity which occurs largely through the block of ion channels in cardiac tissue. It is ironic that the Na V 1.5 channel, which may contribute to beneficial effects of local anaesthetics on metastatic breast and colon cancer cells, is also found in the heart where its block would be detrimental. The presence of the neonatal variant and a predominance of the inactivated state may provide an opportunity to selectively target Na V 1.5 channels in cancer cells by the systemic administration of low concentrations of local anaesthetics or other state-dependent VASC inhibitors.
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